Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Standard Chartered CFO Runs Blindfolded As Seeing Is Believing Becomes Official 2009 Standard Chartered Great City Race Beneficiary
Standard Chartered"s Group Finance Director, Richard Meddings, has pledged to run The Standard Chartered Great City Race 2009 blindfolded to help raise funds for the race"s official community partner, Seeing is Believing (SiB). Today, organisers call for the other runners to start fundraising and help make a difference*.

Doctor Knows Best - Royal College Of Obstetricians And Gynaecologists
In a commentary published in BJOG: An International Journal of Obstetrics and Gynaecology, doctors discuss the types of information pregnant women would welcome and why the advice provided to women by doctors is considered trustworthy.
News of the day
Hundreds Gather For California Rally Protesting Proposed Cuts To HIV/AIDS Programs
Hundreds of people gathered at a planned rally on Wednesday at the California State Capitol in Sacramento to protest the proposed $80.1 million in budget cuts to HIV/AIDS programs in the state, which would result in an 80 percent reduction in prevention, testing and counseling programs, as well as significant cuts in programs for people living with HIV, the San Francisco Chronicle reports. According to the Chronicle, the budget plan "faces pushback from the Legislature, where the leaders of both houses have announced their strong opposition," including Sen. Mark Leno (D). At the rally, Leno urged other lawmakers to examine the possible effects of the cuts. Lisa Page, a spokesperson for Gov. Arnold Schwarzenegger (R), said the governor understands the consequences of the cuts but the state is facing a $24.3 billion budget deficit and has limited options. She said, "Many of these cuts the governor would never consider except in a worst-case scenario, and this is the worst-case scenario" (Buchanan, San Francisco Chronicle, 6/11).
Medical Devices

Key Data Related To Plexxikon's Lead Oncology Program PLX4032 To Be Presented At ASCO 2009 Annual Meeting

Plexxikon Inc., announced that key data related to PLX4032 and its development, will be presented in three separate presentations at the American Society of Clinical Oncology (ASCO) 2009 Annual Meeting taking place May 29 through June 2, 2009 in Orlando, Florida. The presentation information is as follows: - Abstract #9021: "PLX4032, a highly selective BRAFV600E kinase inhibitor: correlation of activity with pharmacokinetic and pharmacodynamic parameters in a Phase 1 trial" - Poster to be presented on May 30, 2009, 8:00 a.m. - 12:00 p.m. EDT by Igor Puzanov, M.D., assistant professor of medicine, Vanderbilt University Medical Center, in the melanoma poster discussion session - Abstract #11003: "Selecting subjects for a therapeutic target in colorectal cancer (CRC): Using a clinical database to enrich for patients harboring the BRAFV600E mutation" - Oral presentation to be made on June 1, 2009, 9:30 a.m. EDT by Jeanne Tie from the Ludwig Institute for Cancer Research in the "Tumor Biology and Human Genetics" session - Abstract #9000 : "Phase 1 study of PLX4032: Proof-of-concept for V600E BRAF mutation as a therapeutic target in human cancer" - Oral presentation to be made on June 1, 2009, 4:30 p.m. to 6:00 p.m. EDT by Keith T. Flaherty, assistant professor, University of Pennsylvania Abramson Cancer Center, in the "Molecular Phenotype of Melanoma Subtypes and Patient-Specific Therapy" session. Link to video clip of Dr. Flaherty. About PLX4032 (R7204)-A Personalized Medicine for Cancer Treatment PLX4032 is a novel, oral small molecule for the treatment of melanoma and other cancers harboring the V600E mutation of the BRAF kinase gene. This defect is present in approximately 60 percent of melanoma skin cancers, and occurs in about eight percent of all solid tumors, including melanoma, colorectal, thyroid and other cancers. Preclinical data suggest that Plexxikon"s novel anti-cancer compound selectively targets and regresses tumors which contain this cancer-causing mutation. In contrast to many other kinase inhibitors available, PLX4032 is highly selective for its primary target, and does not have significant activity on other kinase targets. Plexxikon


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009